12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Gevokizumab: Interim Phase II data

Interim data from a double-blind, U.S. Phase II proof-of-concept trial in 92 evaluable patients with moderate to severe acne vulgaris showed that once-monthly 0.6 mg/kg subcutaneous gevokizumab significantly reduced mean inflammatory facial lesion count from baseline to day 42 vs. placebo (19 vs. 13 lesion count reduction, p=0.077). However, high-dose gevokizumab did not significantly reduce mean inflammatory facial lesion count from baseline to day 84, the primary endpoint, vs. placebo. Xoma said statistical significance on the...

Read the full 359 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >